WO1999051735A3 - Mapkap kinase 2-hemmer und ihre verwendung für die anti-inflammatorische therapie - Google Patents

Mapkap kinase 2-hemmer und ihre verwendung für die anti-inflammatorische therapie Download PDF

Info

Publication number
WO1999051735A3
WO1999051735A3 PCT/DE1999/000990 DE9900990W WO9951735A3 WO 1999051735 A3 WO1999051735 A3 WO 1999051735A3 DE 9900990 W DE9900990 W DE 9900990W WO 9951735 A3 WO9951735 A3 WO 9951735A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
mapkap kinase
inflammatory therapy
therapy
mapkap
Prior art date
Application number
PCT/DE1999/000990
Other languages
English (en)
French (fr)
Other versions
WO1999051735A2 (de
Inventor
Alexey Kotlyarov
Matthias Gaestel
Carola Schubert
Armin Neininger
Original Assignee
Max Delbrueck Centrum
Alexey Kotlyarov
Matthias Gaestel
Carola Schubert
Armin Neininger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum, Alexey Kotlyarov, Matthias Gaestel, Carola Schubert, Armin Neininger filed Critical Max Delbrueck Centrum
Priority to JP2000542448A priority Critical patent/JP2002510714A/ja
Priority to US09/647,701 priority patent/US6683172B1/en
Priority to EP99924743A priority patent/EP1108016A2/de
Publication of WO1999051735A2 publication Critical patent/WO1999051735A2/de
Publication of WO1999051735A3 publication Critical patent/WO1999051735A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Die Erfindung betrifft MAPKAP Kinase 2-Hemmer und ihre Verwendung für die anti-inflammatorische Therapie. Anwendungsgebiete der Erfindung sind die Medizin und die pharmazeutische Industrie. Gemäss der Erfindung werden MAPKAP Kinase 2-Hemmer auf der Genebene, auf der Proteinebene und auf der Basis einer spezifischen Veränderung der intrazellulären Lokalisation der MAPKAP Kinase 2 eingesetzt. Die Erfindung ermöglicht eine gezielte Therapie der Entzündungsantwort und kann somit für die moderne Medizin von grundlegender Bedeutung sein.
PCT/DE1999/000990 1998-04-03 1999-04-01 Mapkap kinase 2-hemmer und ihre verwendung für die anti-inflammatorische therapie WO1999051735A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000542448A JP2002510714A (ja) 1998-04-03 1999-04-01 Ｍａｐｋａｐキナーゼ−２阻害剤および抗炎症治療におけるその使用
US09/647,701 US6683172B1 (en) 1998-04-03 1999-04-01 Mapkap kinase 2-inhibitors and the use thereof in anti-inflammatory therapy
EP99924743A EP1108016A2 (de) 1998-04-03 1999-04-01 Mapkap kinase 2-hemmer und ihre verwendung für die anti-inflammatorische therapie

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19814963A DE19814963A1 (de) 1998-04-03 1998-04-03 MAPKAP Kinase 2-Hemmer und ihre Verwendung für die anti-inflammatorische Therapie
DE19814963.8 1998-04-03

Publications (2)

Publication Number Publication Date
WO1999051735A2 WO1999051735A2 (de) 1999-10-14
WO1999051735A3 true WO1999051735A3 (de) 2001-04-12

Family

ID=7863483

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1999/000990 WO1999051735A2 (de) 1998-04-03 1999-04-01 Mapkap kinase 2-hemmer und ihre verwendung für die anti-inflammatorische therapie

Country Status (5)

Country Link
US (1) US6683172B1 (de)
EP (1) EP1108016A2 (de)
JP (1) JP2002510714A (de)
DE (1) DE19814963A1 (de)
WO (1) WO1999051735A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6909001B2 (en) 2002-12-12 2005-06-21 Pharmacia Corporation Method of making tricyclic aminocyanopyridine compounds
US8440610B2 (en) * 2004-11-12 2013-05-14 Massachusetts Institute Of Technology Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells
AU2005304638A1 (en) * 2004-11-12 2006-05-18 Massachusetts Institute Of Technology Methods and compositions for treating cellular proliferative diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034137A2 (en) * 1996-03-12 1997-09-18 Smithkline Beecham Corporation Methods of the identification of pharmaceutically active compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034137A2 (en) * 1996-03-12 1997-09-18 Smithkline Beecham Corporation Methods of the identification of pharmaceutically active compounds

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CUENDA A ET AL: "SB 203580 IS A SPECIFIC INHIBITOR OF A MAP KINASE HOMOLOGUE WHICH IS STIMULATED BY CELLULAR STRESSES AND INTERLEUKIN-1", FEBS LETTERS, vol. 364, no. 2, 8 May 1995 (1995-05-08), pages 229 - 233, XP000567769, ISSN: 0014-5793 *
ENGEL K. ET AL.: "Leptomycin B-sensitive nuclear export of MAPKAP kinase 2 is regulated by phosphorylation.", EMBO J 1998 JUN 15;17(12):3363-71, XP002120627 *
ROUSE J ET AL: "A NOVEL KINASE CASCADE TRIGGERED BY STRESS AND HEAT SHOCK THAT STIMULATES MAPKAP KINASE-2 AND PHOSPHORYLATION OF THE SMALL HEAT SHOCK PROTEINS", CELL, vol. 78, 23 September 1994 (1994-09-23), pages 1027 - 1037, XP002041232, ISSN: 0092-8674 *
STOKOE D. ET AL.: "MAPKAP kinase-2;a novel protein kinase activated by mitogen-activated protein kinase.", EMBO J 1992 NOV;11(11):3985-9, XP002120626 *
TAN Y ET AL: "FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2.", EMBO JOURNAL, (1996 SEP 2) 15 (17) 4629-42., XP002120625 *
ZU YL. ET AL.: "Activation of MAP kinase-activated protein kinase 2 in human neutrophils after phorbol ester or fMLP peptide stimulation.", BLOOD 1996 JUN 15;87(12):5287-96, XP002120624 *

Also Published As

Publication number Publication date
JP2002510714A (ja) 2002-04-09
EP1108016A2 (de) 2001-06-20
WO1999051735A2 (de) 1999-10-14
DE19814963A1 (de) 1999-10-07
US6683172B1 (en) 2004-01-27

Similar Documents

Publication Publication Date Title
NO973222D0 (no) Nye farnesyl-transferase-inhibitorer, deres fremstilling samt farmasöytiske preparater inneholdende inhibitorene
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
EP1449834A3 (de) Hemmung der RAF-Kinase unter Verwendung von symmetrisch und unsymmetrisch substituierten Harnstoffen
AU2002343557A1 (en) Substituted aryl 1,4-pyrazine derivatives
WO1999054286A3 (en) Btk inhibitors and methods for their identification and use
NO20035763L (no) Tetrahydrokinolinderivater, farmasøytiske preparater omfattende slike samt anvendelse av slike for fremstilling av medikament for kontroll av fruktbarhet.
NO973608D0 (no) Nye farnesyl-transferaseinhibitorer, deres fremstilling samt farmasöytiske preparater inneholdende forbindelsene
DZ3191A1 (fr) Composés d'indazole et compositions pharmaceutiques inhibant les protéines kinases, et procédés d'utilisation de ceux-ci.
HK1019560A1 (en) Formulation for use in the prevention of pathogen induced diseases including hiv and hsv.
BR9814956A (pt) Inibidores de benzotiazol da tirosina cinase de proteìna
CA2216535A1 (en) Protein kinase c inhibitors
NO20042694L (no) 17 alfa-alkyl-17 beta-oksy-ostratriener og mellomprodukter for fremstilling av disse, anvendelse av 17 alfa-alkyl-17 beta-oksy-ostratrienene til fremstilling av legemidler samt farmasoytiske preparater
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
AU2002336288A1 (en) Weed controller metabolism proteins, genes thereof and use of the same
EP0793660A4 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1-dioxiden, zusammensetzung und deren verwendung
HUP9802926A2 (hu) Apolipoprotein A-I új variánsai
WO2003045309A3 (en) Peptides, peptide compositions,and methods of use in binding p 185
WO2003016563A3 (fr) Cible moleculaire de la neurotoxicite
AU2001292019A1 (en) Protein prenyl transferase inhibitors in the treatment of neuroinflammatory disease
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
NO20016247L (no) Streptograminderivater, deres fremstilling samt preparater inneholdende derivatene
NO306060B1 (no) Substituerte kanelsyreguanidider, deres anvendelse samt medikamenter inneholdende guanididene
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
WO1999051735A3 (de) Mapkap kinase 2-hemmer und ihre verwendung für die anti-inflammatorische therapie
AU2002368056A1 (en) Novel pla2 enzyme, it's antibody, enzyme inhibitor and use and the preparation methods thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999924743

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09647701

Country of ref document: US

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWP Wipo information: published in national office

Ref document number: 1999924743

Country of ref document: EP